The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis

Mathias Schneeweiss, Barbara Peter, Siham Bibi, Gregor Eisenwort, Dubravka Smiljkovic, Katharina Blatt, Mohamad Jawhar, Daniela Berger, Gabriele Stefanzl, Susanne Herndlhofer, Georg Greiner, Gregor Hoermann, Emir Hadzijusufovic, Karoline V. Gleixner, Peter Bettelheim, Klaus Geissler, Wolfgang R. Sperr, Andreas Reiter, Michel Arock, and Peter Valent

Disclosures: G.H. received honoraria from Novartis. W.R.S. received honoraria from Novartis and Celgene, and a research grant from Lipomed. A.R. received a research grant from Novartis, honoraria from Novartis and BMS, and served in advisory boards organized by Deciphera, Blueprint, and Baxalta/Shire. M.A. received a research grants from Blueprint and Deciphera, and received honoraria from Deciphera. P.V. received a research grant from Novartis, from Blueprint, and from Deciphera, and received honoraria from Novartis, Celgene, Pfizer, and Deciphera. P.V. and A.R. served as a Consultant in a Novartis trial examining the effects of midostaurin in advanced SM.

Contributions: MS, BP, SB, GE, KB, DB, GS, DS, GG and GH performed research; MJ, AR, KVG, WRS, PB and KG contributed patient samples; SB, MA and EH contributed cell lines; SH provided logistic support; MS and PV performed data analysis; MS and PV wrote the manuscript; PV supervised the study